ATE550352T1 - Verfahren zur herstellung von hybridantikörper - Google Patents

Verfahren zur herstellung von hybridantikörper

Info

Publication number
ATE550352T1
ATE550352T1 AT02794114T AT02794114T ATE550352T1 AT E550352 T1 ATE550352 T1 AT E550352T1 AT 02794114 T AT02794114 T AT 02794114T AT 02794114 T AT02794114 T AT 02794114T AT E550352 T1 ATE550352 T1 AT E550352T1
Authority
AT
Austria
Prior art keywords
hybrid
antibodies
framework regions
hybrid antibodies
antibody fragments
Prior art date
Application number
AT02794114T
Other languages
English (en)
Inventor
Russell Rother
Dayang Wu
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of ATE550352T1 publication Critical patent/ATE550352T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02794114T 2001-12-03 2002-12-03 Verfahren zur herstellung von hybridantikörper ATE550352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33659101P 2001-12-03 2001-12-03
PCT/US2002/038450 WO2003048321A2 (en) 2001-12-03 2002-12-03 Hybrid antibodies

Publications (1)

Publication Number Publication Date
ATE550352T1 true ATE550352T1 (de) 2012-04-15

Family

ID=23316785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794114T ATE550352T1 (de) 2001-12-03 2002-12-03 Verfahren zur herstellung von hybridantikörper

Country Status (12)

Country Link
US (1) US7399594B2 (de)
EP (2) EP1461428B1 (de)
JP (3) JP4723810B2 (de)
AT (1) ATE550352T1 (de)
AU (1) AU2002359568B2 (de)
CA (1) CA2468744C (de)
CY (1) CY1112843T1 (de)
DK (1) DK1461428T3 (de)
ES (1) ES2384100T3 (de)
PT (1) PT1461428E (de)
SI (1) SI1461428T1 (de)
WO (1) WO2003048321A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7393648B2 (en) * 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
AU2003249533A1 (en) * 2002-07-04 2004-01-23 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
WO2005047328A2 (en) * 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
JP2007512846A (ja) * 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
EP1711527A4 (de) * 2003-12-15 2008-09-03 Dendreon Corp Hla-dr-spezifische antikörper, zusammensetzungen und verfahren
WO2005098039A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Method and apparatus for analyzing and generating human antibody amino acid and nucleic acid sequences
US20060263787A1 (en) * 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1907001B1 (de) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3-bindungsmoleküle und ihre verwendungen
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
CA2655903A1 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
WO2009079793A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains
RU2490278C2 (ru) * 2007-12-21 2013-08-20 Медиммун Лимитед ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2742861A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
US8569460B2 (en) * 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
CA2791866A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
KR101834026B1 (ko) 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
JP6482525B2 (ja) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター 高親和性抗ｇｄ２抗体
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
AU689755B2 (en) 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
EP0888125B1 (de) * 1996-03-20 2004-05-26 Immunomedics, Inc. GLYKOSYLIERTE IgG ANTIKÖRPER
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1436329A4 (de) * 2001-09-20 2005-04-27 Alexion Pharma Inc Anti-pdgf-antikörper und verfahren zur herstellung konstruierter antikörper
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules

Also Published As

Publication number Publication date
EP2298817A1 (de) 2011-03-23
AU2002359568B2 (en) 2008-02-21
JP4723810B2 (ja) 2011-07-13
JP5054058B2 (ja) 2012-10-24
JP2012144551A (ja) 2012-08-02
US7399594B2 (en) 2008-07-15
AU2002359568A1 (en) 2003-06-17
SI1461428T1 (sl) 2012-07-31
EP1461428A4 (de) 2005-05-25
WO2003048321A3 (en) 2003-10-16
PT1461428E (pt) 2012-05-29
CY1112843T1 (el) 2016-02-10
ES2384100T3 (es) 2012-06-29
CA2468744A1 (en) 2003-06-12
WO2003048321A2 (en) 2003-06-12
US20030219861A1 (en) 2003-11-27
JP2009153527A (ja) 2009-07-16
JP2005511706A (ja) 2005-04-28
DK1461428T3 (da) 2012-06-04
EP1461428B1 (de) 2012-03-21
EP1461428A2 (de) 2004-09-29
CA2468744C (en) 2013-05-14

Similar Documents

Publication Publication Date Title
ATE550352T1 (de) Verfahren zur herstellung von hybridantikörper
WO2004108889A3 (en) Hybrid antibodies
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
ITRM20030601A1 (it) Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
DE69842174D1 (de) Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
ATE368095T1 (de) Verfahren zur herstellung von mitteldistillaten
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
DE60235588D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
IL213524A0 (en) Method for removing blood group antigens in serum
DE60232618D1 (de) Mikrofluidische Vorrichtung, Verfahren zur Herstellung und Verwendung desselben
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
DE60330099D1 (de) Verfahren und Anordnungen zur Herstellung, Feststellung und Übertragung von Identifikatoren
ATE557040T1 (de) Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
WO2003097812A3 (en) Transgenic ungulates capable of human antibody production
ATE297430T1 (de) Verfahren zur herstellung von tannin und seine verwendung
ATE358172T1 (de) Verfahren zur herstellung von olefinen.
ATE423467T1 (de) Verfahren zur herstellung von genetisch modifizierten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften
ATE286037T1 (de) Verfahren zur herstellung von 5-substituierten isobenzofuranen
WO2023154814A3 (en) Shbg and ibp4 antibodies and methods using same
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof